Meet The Team

Biomedical research is newly enabled by advances in human genomic and proteomic technologies. We are committed to fully utilizing these technologies to construct a more efficient roadmap for drug discovery.

We are excited to be expanding our team to elucidate protein community dynamics and develop important new medicines for common diseases.

Zach Sweeney

CEO

Click to expand a panel.

Founding Scientific Advisors

Board Of Directors

Growing Community

John Chodera

John Chodera

Founding Scientific Advisor

John Chodera is an experienced computational chemist, and an Associate Member at Sloan Kettering Institute for Cancer Research (MSKKC). His research combines the disciplines of statistical mechanics, biomolecular simulation, and biophysical measurements to develop quantitative models for predicting and understanding how small molecules selectively bind biomolecular targets, how binding modulates conformation and function, and how mutations can perturb drug binding affinities to cause drug resistance.

John has authored over 75 articles in peer-reviewed journals, which have collectively received over 12,500 literature citations. John has also received numerous awards including the BIH Einstein Visiting Fellowship, Silicon Therapeutics Open Science Fellowship, Louis V. Gerstner Young Investigator Award, QB3-Berkeley Distinguished Postdoctoral Fellowship, IBM Predoctoral Fellowship, the Frank M. Goyan Award for outstanding work in Physical Chemistry at UCSF, and a HHMI Predoctoral Fellowship.

John holds a B.S. in Biology from Caltech and a Ph.D. in Biophysics from the University of California, San Francisco. He completed postdoctoral studies at Stanford University and at University of California, Berkeley as a QB3 Fellow.

Affiliations

  • Memorial Sloan Kettering

Social Media

  • LinkedIn
Wade Harper

Wade Harper

Founding Scientific Advisor

Wade Harper is a seasoned cellular biologist whose research is focused on the analysis of ubiquitin-driven signaling systems and the integration of quantitative proteomics and cell biology to understand the mechanism for the signaling systems.

Wade is the Bert and Natalie Vallee Professor of Molecular Pathology and Chairman of the Department of Cell Biology at Harvard Medical School, and co-Director of the Dana Farber-Harvard Cancer Center Cancer Cell Biology Program. His lab has used proteomic approaches to define the interaction networks of various protein families (deubiquitinating enzymes, F-box proteins) and signaling networks (autophagy, ERAD, CRLs, Parkin), as well as to define the ubiquitin-modified proteome.

Wade has received many awards, including the American Cancer Society Junior Faculty Award, the Michael DeBakey Award for Excellence in Research in both 1994 and 2000, and the Javits award from the National Institute of Health. Wade received his doctorate in chemistry at the Georgia Institute of Technology prior to completing postdoctoral studies in biological chemistry at Harvard Medical School.

Affiliations

  • Harvard Medical School
  • Dana Farber Cancer Center

Social Media

  • LinkedIn
Nevan Krogan

Nevan Krogan

Founding Scientific Advisor

Nevan Krogan is a leading molecular and systems biologist whose current research is focused on the generation and analysis of large-scale genetic and protein-protein interaction datasets in a variety of organisms, ranging from bacteria to mammalian cells, with the ultimate goal of developing new therapeutics. To this end, he has developed strategies to generate quantitative genetic interaction maps and affinity tag/purification/mass spectrometry technologies used to create protein-protein interaction maps.

Nevan is a Professor and the Director of the Quantitative Biosciences Institute (QBI) at the University of California San Francisco (UCSF), as well as a Senior Investigator at the J. David Gladstone Institutes. He has authored over 300 papers in the field of molecular biology and has given over 350 lectures and seminars around the world. Nevan obtained his undergraduate degree in chemistry in 1997, his M.Sc. in biology in 1999 from the University of Regina and received his Ph.D. in medical genetics at the University of Toronto in 2006.

Affiliations

  • USCF
  • Gladstone Institutes

Social Media

  • LinkedIn
Brenda Schulman

Brenda Schulman

Founding Scientific Advisor

Brenda Schulman is a leading biochemist and structural biologist. She has substantially contributed to the characterization of ubiquitin-like proteins (UBLs). Her main interest is how ubiquitin-like proteins and ubiquitin are able to specifically modify certain substrates, and how they alter the functions of their targets to regulate biological processes.

Brenda is an elected member of American Academy of Arts and Sciences, the National Academy of Sciences and EMBO. She has been awarded several prizes including the Gottfried Wilhelm Leibniz Prize and Ernst Jung Prize for Medicine.

Brenda received her bachelor’s degree in biology from Johns Hopkins University in 1989 and her Ph.D. in biology from the Massachusetts Institute of Technology in 1996. She was a postdoctoral fellow at the Massachusetts General Hospital Cancer Center and later at the Memorial Sloan Kettering Cancer Center. Brenda joined the faculty at the St. Jude Children’s Research Hospital in 2001 and held the Joseph Simone Endowed Chair of Basic Research as of 2014. She also became a Howard Hughes Medical Institute Investigator in 2005. Brenda moved to the Max Planck Institute in 2017 and is currently the Director at the Institute of Biochemistry.

Affiliations

  • Max Plank Institute

Social Media

  • LinkedIn
Vik Bajaj

Vik Bajaj

Board of Directors, Director

Vik Bajaj is a managing director at Foresite Capital, evaluating and pursuing investments at the intersection of technology and life sciences. Prior to joining Foresite Capital and co-founding Foresite Labs, Vik was the chief scientific officer of GRAIL. He was also co-founder and former chief scientific officer of Verily and served as chair of its Scientific Advisory Board. Vik retains appointments as associate professor (consulting) at the Stanford School of Medicine, and as an affiliate scientist of the Lawrence Berkeley National Laboratory and the University of California, Berkeley, for which he serves on the advisory board of the College of Chemistry. He is an advisor to the Department of Defenses Science Board’s Task Force on Biology.

Vik’s research interests lie at the interface of the physical sciences, engineering, and the life sciences. He holds a Ph.D. in physical chemistry from the Massachusetts Institute of Technology. Vik’s scientific and engineering awards include the Anatole Abragam Prize (2012), the R&D 100 Award for the most promising commercialized technologies (2011 and 2013), and the Department of Energy’s LBL Innovation Grant (2013).

Affiliations

  • Foresite Capital Management

Social Media

  • LinkedIn
Kristina Burow

Kristina Burow

Board of Directors, Board Observer

Kristina Burow is focused on the creation and development of biotechnology, pharmaceutical and health tech companies. Since joining ARCH in 2002, she has risen from Associate to Managing Director and has played a significant role in the growth of ARCH’s life sciences portfolio.

Kristina is a Director of Beam Therapeutics (BEAM), Vividion Therapeutics, Gossamer Bio (GOSS), Metacrine (MTCR), Scholar Rock (SRRK), Unity Biotechnology (UBX), Boundless Bio, Autobahn Therapeutics, ROME Therapeutics, Boragen and AgBiome. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene) and was a Director of VIR Biotechnology (VIR), and Epirium Bio. Kristina has participated and led investments in a number of other ARCH portfolio companies including Erasca, Dewpoint Therapeutics, Mindstrong, Aledade, Kura Oncology (KURA), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), and Ikaria (acquired by Mallinckrodt).

Prior to joining ARCH Kristina was an Associate with the Novartis BioVenture Fund in San Diego. Kristina holds an M.B.A. from the University of Chicago, an M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.

Affiliations

  • Arch Venture Partner

Social Media

  • LinkedIn
Jay Parrish

Jay Parrish

Board of Directors, Director

Jay Parrish is a Venture Partner at ARCH Venture Partners, and co-founder and Chief Business Officer of Vir Biotechnology. He is an accomplished scientist who began his career at Gilead Sciences, Inc. where his research focused on the discovery of small molecule antiviral medicines. In this role, he was involved with several successful discovery campaigns, including as a co-inventor of ledipasvir. Jay then joined Gilead’s Corporate Development team, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company.

Jay holds a B.S. in Chemistry from Emory University and a Ph.D. in Synthetic Organic Chemistry from the University of South Florida. He completed a postdoctoral fellowship at the Scripps Research Institute and received an M.B.A. from U.C. Berkeley’s Haas School of Business. Jay has authored over 25 peer-reviewed scientific publications and holds over 20 issued patents and applications.

Affiliations

  • Arch Venture Partner

Social Media

  • LinkedIn
Zach Sweeney

Zach Sweeney

Founder, Board of Directors, CEO

Zach Sweeney is the CEO at Interline Therapeutics, an Affiliate at ARCH Venture Partners and a Venture Partner at Foresite Labs. He has broad experience growing and leading successful multifunctional drug discovery groups, including small molecule, biotherapeutic, and AAV discovery platforms.

Zach was previously the Chief Scientific Officer at Denali Therapeutics, where he guided the growth of the discovery portfolio and research group. Prior to joining Denali, Zach was a leader in the drug discovery groups at Revolution Medicines, Novartis, Genentech, and Roche. Molecules that Zach and his teams have developed at these companies have been the subject of several major licensing deals that cumulatively generated more than $1B in upfront payments.

Zach attended Stanford University, where he received a B.S. degree in Chemistry. He subsequently earned a Ph.D. in Chemistry from the University of California, Berkeley, and completed a NIH postdoctoral fellowship at Harvard University. Zach’s research interests include the application of genomic and biomarker information in drug discovery, computational approaches to improve small molecule and biotherapeutic design, and the chemical biology of drug candidates. He is listed as an inventor on approximately 60 published patent applications and has co-authored more than 40 scientific publications.

Affiliations

  • Interline Therapeutics
  • Foresite Labs
  • Arch Venture Partners

Social Media

  • LinkedIn
Jim Tananbaum

Jim Tananbaum

Board of Directors, Chairman

Jim Tananbaum is the founder and CEO of Foresite Capital, a US-focused healthcare investment firm with $3 billion under management.

Jim has been a lead financier and thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics, Amerigroup (NASDAQ: ANTM), and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jim co-founded and initially ran GelTex Pharmaceuticals (NASDAQ: GENZ) and Theravance (NASD: TBPH and INVA). Jim’s investment experience includes being a co-founder of Prospect Ventures and earlier in his career, a partner of Sierra Ventures, where he established its healthcare services investment practice. Jim has been named to Forbes’ Midas List of Top Tech Investors between 2015 to 2018 and in 2021.

Jim received his M.D. and M.B.A. from Harvard, and a Master’s degree from MIT. He graduated with degrees in Applied Math and Electrical Engineering/Computer Science from Yale College.

Affiliations

  • Foresite Capital Management

Social Media

  • LinkedIn
Mike Varney

Mike Varney

Director and Founding Scientific Advisor

Mike Varney is the former Executive Vice President and Head of Genentech Research and Early Development (gRED), where he was responsible for all aspects of drug discovery and development for the US based R&D organization in Roche and served as a member of the Roche Corporate Executive Committee.

Mike began his career in 1987 as one one of the first employees at Agouron. When Pfizer acquired Agouron in 2000, Mike was selected to lead Drug Discovery for Pfizer’s San Diego organization. In 2005, Mike was recruited to Genentech to take the company beyond biologics and create a small molecule drug discovery capability.

Mike holds a B.S. in Chemistry from UCLA, a Ph.D. in synthetic organic chemistry from Caltech and was an American Cancer Society postdoctoral fellow at Columbia.

Affiliations

  • Previously Genentech/Roche and Pfizer

Social Media

  • LinkedIn
Kim Barnash

Kim Barnash

Senior Scientist, Lead Discovery

Kim is a biochemist with a background in organic synthesis. Prior to joining Interline, Kim spent nearly a decade studying chromatin regulation. She obtained her Ph.D. in the lab of Stephen Frye at UNC-Chapel Hill where she developed a combinatorial chemistry platform to discover chemical probes of methyl-lysine readers. Next, she interrogated the biochemical and biophysical regulation of chromatin remodeling complexes at Foghorn Therapeutics. Kim recently returned to California from Massachusetts in her campervan Homer, hiking and exploring the country along the way.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Christine Beahn

Christine Beahn

Director, Corporate Development

Before Interline, Christine was a Director of Business Development, Contracts and Alliances at Calico Life Sciences. Christine was previously on the Genentech Research Portfolio and Operations team and led the Research and Development Contracts group in the global procurement organization. Before Genentech, Christine was in the Technology Transfer Office at the University of Washington and was also one of the first employees of Clinical Advisors LLC (now Guidepoint Global). Christine resides in SF with her husband, two young French speaking children and senior dog, Oso (her most obedient child). Christine received a B.S. from Stanford University and a M.P.H. and Ph.D. from Columbia University.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Mario Cardozo

Mario Cardozo

VP, Computational Chemistry

Prior to joining Interline, Mario most recently served as Director of Computational Chemistry at Nurix working on modulators of protein-protein interactions, including bifunctional degraders. Mario also has over 20 year of experience in small molecule drug discovery at Amgen, Tularik, and Boehringer Ingelheim. He has expertise applying a range of CADD methods to a diversity of drug targets, and experience in multiple therapeutics areas. Mario has also developed ligand affinity scoring functions, cheminformatics tools and several ADMET predictive models to support lead identificaiton and lead optimization. Mario was directly involved in the identification of 12 drug candidates and 3 that advanced into clinical studies. Mario received a Pharm.D. as well as an M.S. in physical organic chemistry from the National University of Cordoba and a Ph.D. in Medicinal Chemistry from the University of Buenos Aires, both in Argentina. Mario completed his postdoctoral training in CADD as an NIH-Fogarty Fellow at The University of Illinois at Chicago.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Shannon Chi

Shannon Chi

Operations

Shannon brings manys years of scientific, legal and operational experience to the Operations role at Interline. She began her career in science at Millennium Pharmaceuticals, then transitioned to patent law at Townsend and Townsend and Crew, before joining the legal group at Genentech in 2007. At Genentech, Shannon has held various roles in patent counseling and IP operations. Shannon received her B.S. in Chemistry from the University of Michigan, Ann Arbor (GO BLUE!) and her Ph.D. in Chemistry from the University of California, Berkeley. Shannon currently lives near San Francisco with her husband, two teens, one pandemic rescue dog and nine chickens.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Nick Galli

Nick Galli

COO

Nick brings extensive experience in corporate development, strategy and operations to his role as Chief Operating Officer. Most recently Nick was CBO at CytomX Therapeutics, where he led the execution of its multi-target collaboration with Astellas. Prior to that, he was VP, Business Development and Alliance Management at Denali Therapeutics, where he closed more than twenty deals, including strategic partnerships with Sanofi, Takeda, Genentech and F-star. Before Denali, Nick was Senior Director, Transactions at the J&J Innovation Center, as well as a member of the business development and transactional law groups at Genentech. He began his career as a corporate attorney at Skadden Arps Slate Meagher & Flom and practiced in the technology transactions group at Wilson Sonsini Goodrich & Rosati. Nick received his A.B. from Princeton and his J.D. from Georgetown. Nick is an avid table tennis player and also enjoys hiking with his rescue dog Donut.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Maris Gonzales

Maris Gonzales

Executive Assistant and Office Manager

Maris brings many years of experience as an executive assistant and office manager to her role at Interline. Maris worked her way through school and received a bachelor’s degree in International Business at the Manuel L Quezon University and later received a degree in Sales and Marketing. She has extensive experience working not only in startup environments, but also, for larger companies, including Pfizer, Bayer, UCSF Medical Center, Nodality, Genesys, Oracle, Sybase and BlackRock.

Maris is passionate about health and fitness, and enjoys spinning, yoga, horse-back riding, wakeboarding, and tango. Lastly but most importantly, she is a proud single-mom in San Francisco.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Zuojun Guo

Zuojun Guo

Senior Scientist , Computational Chemistry

Zuojun (George) Guo, Ph.D is Senior Scientist of Computational Chemistry at Interline, and has more than 8 years of experience in computational guided drug design. Zuojun most recently served as a Senior Scientist at Plexxikon, where he was a key contributor to a robust structure-based drug design platform. At Plexxikon, Zuojun worked on over 20 research projects across various therapeutic areas, and delivered more than 6 development candidates with desired target property profiles. Prior to Plexxikon, Zuojun conducted postdoctoral training at Pfizer and Novartis in inflammation & oncology. He received his Ph.D. in Computational Biochemistry from Boston College and a MS of Polymer Physics from Fudan University, Shanghai.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Kara Halvorsen

Kara Halvorsen

Head of HR

Kara Halvorsen joined Interline Therapeutics as consulting Head of HR in February of 2021. She has 20+ years of HR leadership experience with deep expertise in talent acquisition, compensation, & organizational development. Kara has consulted with more than thirty companies, including opening seven biotech companies, supporting several through their IPOs, including 89bio and Audentes Therapeutics. She began her life science career at Genentech where she played a key role in launching their Bio-Oncology franchise.

Prior to working in Human Resources, Kara was a commercial lender for California’s second-largest bank. She has a B.S in Organizational Development from the University of San Francisco. Kara is passionate about her family, blues & jazz, food & wine and hiking in Marin.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Roberta Hannibal

Roberta Hannibal

Senior Scientist, Cell Biology

Roberta’s foremost research interest is how genetic code is translated into phenotypic variation. She has pursued this topic throughout her career using a variety of techniques in cell, developmental, and evolutionary biology, as well as genetics and genomics. Roberta is excited to apply foundational genetic insights to drug discovery at Interline.

Raised by a librarian and a geologist in Cleveland, OH, Roberta’s scientific career has a westward trajectory. After completing her undergraduate studies at the University of Chicago, Roberta joined Nipam Patel’s lab at UC Berkeley to earn her Ph.D. in Molecular and Cell Biology. At Cal, Roberta studied evolutionary developmental biology using an amphipod crustacean as a model system. Following grad school, Roberta joined Julie Baker’s lab at Stanford. In the Baker lab, Roberta discovered a novel mechanism of mammalian gene regulation, in which placental trophoblast giant cells tailor gene copy number to modulate the expression of critical genes. Roberta then courageously surrendered to the call of discovery biology in biotech, and joined Second Genome, where she identified and characterized microbial proteins and peptides that interact with human immune cells to modulate human health.

When not at the bench or spending time with her family, Roberta enjoys running and growing succulents.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Stacy Holland

Stacy Holland

Head of Finance

Stacy Holland is currently the financial and accounting advisor for Interline Therapeutics. She most recently served as Chief Financial Officer for a multi-national subsidiary of Dover Corporation with responsibility for financial matters, regulatory compliance and information technology services. She previously held auditing, accounting and management positions at Deloitte LLC, Rockwell Automation and Briggs and Stratton.

Stacy is a Certified Public Accountant and a graduate of the University of Wisconsin-Milwaukee. In her free time, Stacy can be found working on her golf game or refining her tennis serve.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
John Klimek

John Klimek

Scientist Proteomics

John Klimek has more than 15 years of experience in proteomics core facilities at the Institute for Systems Biology in Seattle and Oregon Health and Science University in Portland. Much of John’s research has centered around the creation and use of standardized test mixtures to design and improve software used in protein identification and quantification. He has also been involved with dozens of proteomics research projects using TMT labeling, which has resulted in several publications.

John’s free time is often spent with his wife and 3 kids, exploring nature and various museums and historical sites.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Don Kirkpatrick

Don Kirkpatrick

VP, CTO

For over 20 years, Don has employed mass spectrometry proteomics to study ‘the most important protein in human cells’ – ubiquitin. As a National Hispanic Scholar, he earned a B.S. in Biochemistry at the University of Oklahoma and received a Ph.D. in Pharmacology and Toxicology at the University of Arizona. First as a Ph.D. student, and then as a postdoctoral fellow at Harvard Medical School, Don published seminal work on polyubiquitin chains and the ubiquitination of proteins including EGFR and cyclin B. He continued this work during his 13 years as a group leader at Genentech, overseeing development of MS proteomics technologies and their application to drug discovery. Don has published more than 80 peer reviewed papers and served on the editorial boards for Molecular & Cellular Proteomics and the Journal of Proteome Research. In addition to ubiquitin, Don is passionate about Dodger baseball, Sooner football and spending time in the mountains with his wife Tarrah and their four children.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Bob Moreau

Bob Moreau

Associate Director, Medicinal Chemistry

Bob is Associate Director of Medicinal Chemistry and brings over 12 years of drug discovery experience to Interline. Bob was previously Senior Principal Scientist at Novartis Institutes for Biomedical Research (NIBR), where he led several structurally-enabled oncology, virology and bacteriology programs to various milestones. Bob began his medicinal chemistry career by contributing to phenotypic drug discovery programs focused on neglected tropical diseases at the Genomics Institute of the Novartis Research Foundation (GNF). Bob earned his Ph.D. in synthetic organic chemistry from Princeton University and B.A. in chemistry from College of the Holy Cross. Outside of work, Bob enjoys cooking and exploring the many Bay Area hiking trails with his family.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Aditya Murthy

Aditya Murthy

Director, Cell Biology

Adi is an immunologist and cell biologist investigating how human genetics of complex diseases informs us about inflammatory signaling. Understanding the mechanism(s) by which a disease-relevant gene governs cellular function is key to developing meaningful therapies. Before joining Interline, Adi was a Senior Scientist and group leader in the Department of Cancer Immunology (2014-2021) and a postdoctoral fellow in the Department of Immunology at Genentech (2011-2014). There, his team investigated innate immunity in cancer and chronic inflammatory diseases with a focus on protein quality control and autophagy.

Adi completed his undergraduate studies at the University of Toronto and performed his doctoral studies at the Ontario Cancer Institute, Department of Medical Biophysics at the University of Toronto. While there, Adi embraced cycling to commute, stay fit and be part of a vibrant community as a local club rider. He’s always looking for new rides in the Bay Area!

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
David Nusinow

David Nusinow

Principal Scientist, Bioinformatics

David obtained his B.S. in Molecular, Cell and Developmental Biology at UCLA and before going on for his Ph.D. at Tufts in the lab of Victor Hatini. There, David established expertise in genetics and imaging based assays while exploring the molecular mechanisms of Drosophila wing development. With a growing interest in computational biology, David went on to postdoc with Shamil Sunyaev at Brigham and Women’s Hospital where he worked as part of the SysCODE Consortium and began to explore the field of proteomics. To further expand his expertise in this area, David served as a Research Fellow in Steven Gygi’s lab at Harvard Med School where he worked on numerous projects in the areas of protein interactions, post-translational modifications, chemical biology and advanced data acquisition. David’s signature work during this period involved systematic proteomic characterization of the cancer cell line encyclopedia (CCLE). Prior to joining Interline, David worked at Pfizer as a Senior Computational Biologist. He resides in the Boston suburbs with his wife and two children.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Naomi Rajapaksa

Naomi Rajapaksa

Principal Scientist Medicinal Chemistry

Naomi is a medicinal chemist at Interline with over seven years of experience in structure- and property-based drug design. She started her industrial career at the Novartis Institutes for Biomedical Research in the area of antiviral drug discovery. Prior to Interline, she was a Senior Scientist and team leader at Genentech, where she contributed to the medicinal chemistry efforts on projects in immunology and oncology. Naomi received a Ph.D. in organic chemistry from Harvard University under the guidance of Eric Jacobsen, studying asymmetric catalysis and synthesis, and a B.S. in chemistry from Stanford University. In her spare time, Naomi enjoys traveling and trying new cuisines.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Meera Rao

Meera Rao

Senior Scientist, Medicinal Chemistry

Meera is a medicinal chemist at Interline. She obtained her Ph.D. from Stanford University, where she developed chiral ruthenium catalysts for cycloisomerization reactions. Meera then completed postdoctoral work at UC Berkeley, where she studied polymer additive effects on enzymatic cellulose degradation. Prior to joining Interline, Meera developed new linker-drugs for antibody-drug conjugates at Stemcentrx and the discovered small molecule inhibitors of protein secretion at Kezar Life Sciences.

In her spare time, Meera enjoys both baking and eating desserts.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Scott Rosenberg

Scott Rosenberg

Scientist, Discovery Pharmacology

Scott earned his Ph.D. in molecular and structural biology from UC San Diego in the laboratory of Dr. Kevin Corbett. He subsequently did a Postdoctoral fellowship at Genentech in the department of Discovery Oncology under Dr. Shiva Malek. During his time at Genentech, he studied mechanisms of targeted protein degradation using structural biology and biophysics. Scott is motivated by the opportunity to translate advancements in science and technology into therapeutic interventions for patients. His favorite pastime is eating a Hawaiian breakfast after a nice morning of surfing.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Srirupa Roy

Srirupa Roy

Scientist, Cell Biology

Srirupa is a cell biologist passionate about exploring diverse cell biology platforms to enable drug discovery. She received her Ph.D. in toxicology from UC Denver, and completed her postdoctoral research in Jay Debnath’s lab in UCSF, where she investigated the role of autophagy in cancer metabolism. Before joining Interline she was a researcher at Genentech, where she designed cell therapy strategies for preclinical models of solid tumors. Previously, Srirupta was also a research scientist in the immunooncology antibody discovery group of Bayer Healthcare.

Outside of work, Srirupa enjoys reading, cooking and spending time outdoors with family.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Anj Saha

Anj Saha

VP, Discovery Pharmacology

Anj joined Interline Therapeutics in January 2021. Prior to that he was an EIR at 5AM Ventures, where he was involved with several early seed companies. Previously, he was at Nurix Therapeutics, where he built and headed the Lead Discovery department. There his team helped discover and progress first in class small molecules against novel E3 ligases and degraders in the fields of oncology and immuno-oncology that are currently in clinical and pre-clinical development. Prior to Nurix, Anj was Director of Biology at Proteostasis Therapeutics and started his industry career at GlaxoSmithKline as an Investigator within Cancer Research.

Anj completed his undergraduate studies in India at IIT-Delhi and received a Ph.D. in Biochemistry working on chromatin biology with Prof. Bradley Cairns at University of Utah. He completed postdoctoral training as a Leukemia and Lymphoma Society Fellow working on ubiquitin ligases with Prof. Raymond Deshaies at Caltech.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Kyle Simonetta

Kyle Simonetta

Director, Lead Discovery

Kyle is a biochemist and structural biologist, with a passion for identifying and progressing small molecules that modulate protein-protein interactions, especially those that form cooperative ternary complexes. At Interline, Kyle leads a team of talented scientists in the biophysical and structural characterization of protein-protein interactions and the discovery of small molecule effectors of those interactions. Kyle received a Ph.D. from UC Berkeley in the laboratory of John Kuriyan, studying the structural mechanisms of DNA replication and subsequently conducted postdoctoral research in the ubiquitin field in Micha Rape’s lab. Most recently, he worked in the field of targeted degradation as the first employee at Nurix Therapeutics, developing molecular glues and heterobifunctional molecules that recruit targets to ubiquitin ligases for ubiquitylation and degradation. He is a 17 year Bay Area transplant from New England (Go Sox!) and enjoys hiking and going on trips with his family.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Jessica Spradlin

Jessica Spradlin

Scientist, Proteomics

Jessica grew up in the Bay Area before attending Tufts University for undergraduate studies in chemistry. She earned her Ph.D. in chemistry at UC Berkeley, working in the lab of Dan Nomura. During her time at Berkeley, Jessica used chemoproteomic methods to study the natural product nimbolide and developed the natural product into an E3-ligase recruiter for targeted protein degradation. At Berkeley, Jessica was awarded the F31 Individual Predoctoral fellowship by the NIH to support her work and also received the “team spirit” award on the aptly named Off-Targets softball team. After graduate school Jessica became interested in using proteomic methods to study protein interactions and went to Genentech as a postdoctoral researcher. She joined Interline as a scientist in June of 2021, leveraging proteomic technologies to improve understanding of dynamic protein communities. Outside of the lab, Jessica enjoys hiking with her dog Moose and keeping busy with DIY projects.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
David Tully

David Tully

VP, Medicinal Chemistry

David Tully brings over 20 years of medicinal chemistry and drug discovery experience to Interline. David was previously Director of Chemistry at the Novartis Institutes for Biomedical Research (NIBR) where he led discovery chemistry research teams across multiple disease areas working on molecular glues and targeted protein degradation. He also led the antiviral medicinal chemistry efforts in the NIBR Infectious Diseases Area. David began his career in drug discovery at the Genomics Institute of the Novartis Research Foundation, where he led the medicinal chemistry efforts on a number of projects in neuroscience, metabolic, respiratory, and infectious diseases that delivered several clinical stage compounds into the Novartis pipeline. When he is not working to discover new drugs, David enjoys mountain biking, hiking, and skiing. David earned his Ph.D. in organic chemistry from the University of California, Berkeley, and a B.S. in chemistry from the University of Minnesota.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Erik Verschueren

Erik Verschueren

Senior Bioinformatics Fellow

Erik joined Interline as a consulting Senior Bioinformatics Fellow in August 2021. His experience spans the fields of proteomics, structural and computational biology, and includes leadership of technical and scientific teams around the world. Erik received his Ph.D. from the CRG in Barcelona in the lab of Luis Serrano, where his research involved computational modeling of peptide-protein interactions. Erik subsequently joined Nevan Krogan’s lab at UCSF, where his work was central to establishing the bioinformatics pipeline for systematically characterizing protein interaction networks. Scientifically, Erik contributed significantly to several host-virus interactome projects and publications for pathogens, including Kaposi’s sarcoma herpes virus (KSHV), hepatitis C, influenza, West Nile and HIV.

Erik also has worked as a Bioinformatics Scientist at Genentech, where he contributed to a wide range of proteomics projects, including characterization of autophagy, cell death, and protein interactions. Most notable amongst these was a landmark contribution in Cell describing the screening of ~600K potential interactions between secreted proteins and immunoglobulin (Ig) superfamily proteins. He then joined Galapagos as an Associate Director of Bioinformatics.

Erik resides in Belgium with his wife Anne and their two children.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Daniela Mavrici

Daniela Mavrici

Senior Scientist, Lead Discovery

Daniela is a protein chemist with a background in structural biology. She has more than 15 years of experience on working with proteins at the bench in different settings. Among other positions, Daniela spent four years at Plexxikon where she worked in the protein chemistry department and contributed to its platform by providing purified drug targets for assays and structural biology. Daniela received her PhD from University of Calabria, Italy meanwhile she conducted her research in Tom Alber’s laboratory at University of California, Berkeley.

When not working, Daniela enjoys spending time outdoors with her family, gardening and cooking.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Tess Branon

Tess Branon

Scientist, Proteomics

Chemist by training and biologist by trade, Tess is interested in understanding the mechanisms of biological interactions at the molecular, cellular, and organismal level. Daughter of Mexican and Korean immigrants, Tess is a North Carolina native who received her undergraduate degrees from Western Carolina University. She then went on to work with Professor Alice Ting at MIT and Stanford University for her PhD where she engineered new proximity labeling tools such as TurboID for proteomic mapping, and worked collaboratively with hundreds of scientists to apply her novel technologies in living cells and organisms. Tess then went on to work with Professor Gregory Barton at the University of California, Berkeley for her postdoctoral training as a Damon Runyon Cancer Research Foundation Robert Black Fellow where she studied host-microbiome interactions in the gut. Outside of the lab, Tess enjoys organizing for social justice reforms by day and dinner parties with friends by night.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Atiqah Mazli

Atiqah Mazli

Research Associate, Proteomics

Atiqah is an aspiring chemist who is interested in learning more about drug discovery. She started her degree in Massachusetts and transferred to University of Minnesota Twin Cities to complete her studies. While at Minnesota, she worked in Dr. Christine Salomon’s lab on a project studying novel natural products for useful biological activities on samples from New Zealand. Afterwards, she worked for two years at mProbe as a research assistant in mass spectrometry. Atiqah is excited to use mass spectrometry as a tool or vehicle to understand and resolve the underlying biological activity and related problems.

During her free time, she enjoys cooking, socializing, and doing outdoor activities.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Jian Payandeh

Jian Payandeh

Sr. Director, Analytical & Structural Proteomics

Jian is biochemist and structural biologist with a keen interest to establish robust methods to advance discovery efforts on challenging targets. Before joining Interline, Jian was a Senior Principle Scientist and Project Team Leader at Genentech where he collaborated broadly to pursue small molecule and antibody discovery approaches against unprecedented membrane protein targets. Resulting structure-function studies have reported on the regulation of Nav1.7 and NALCN sodium channels, the pharmacological modulation of ABC transporters, the mechanism of therapeutic antibodies, and the role of essential bacterial proteins in regulating cell envelop biogenesis. At Interline, Jian will help the team integrate emerging technologies to uncover the dynamic underpinnings of protein communities for therapeutic targeting.

Jian pursued his undergraduate degree at McGill University, graduate school at the University of Toronto, and postdoctoral studies at the University of Washington. In his spare time, Jian enjoys being an exceptional husband and father and perfecting his Canadian sarcasm.

 

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Jason Liang

Jason Liang

Scientist, Proteomics

Jason is a trained biochemist and received his Ph.D. in Chemistry at UC San Diego in the lab of Huilin Zhou at the Ludwig Institute for Cancer Research. There he developed methods utilizing mass spectrometry to study protein sumoylation and its functions in genome maintenance. He then went on to join Genentech in the labs of Donald Kirkpatrick and Shiva Malek as a Postdoctoral fellow, where he employed advanced technologies in quantitative proteomics to study RAF complexes in cancer cells. Jason has a keen interest in using biochemistry and proteomics to understand the mechanisms and regulation of signaling pathways, and is excited at the opportunity to develop and apply these cutting edge technologies to drug discovery. When he is not in the lab, Jason enjoys exploring the outdoors – hiking, snowboarding, and finding new places to share a good meal with his family and friends.  

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Hart Rardin

Hart Rardin

Principal Scientist, Cell Biology

 Hart is an immunologist interested in the causes of aberrant inflammation that lead to inflammatory diseases. She has over ten years of experience at Genentech as a scientific researcher focused on small molecule therapeutics where she was involved in inhaled JAK1 small molecule inhibitors for the treatment of asthma. She then continued her work on inhaled therapeutics as a Senior Scientist at Theravance prior to joining Interline. Hart completed her undergraduate studies at North Carolina State University and obtained her PhD in immunology in the lab of Dr. Robert Rickert at the Burnham Institute associated with UCSD. Outside of work, Hart enjoys spending time with her family in the great outdoors.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Gard Nelson

Gard Nelson

Principal Scientist, Computational Chemistry

Gard is a computational chemist whose research interests center on free energy calculations of critical molecular processes. His previous role as a principal scientist at ImmunityBio primarily involved calculating binding free energies between drug candidates and cancer or infectious disease targets. These candidates ranged from small molecules to modified protein-protein interfaces. Free energy calculations provide the basis for optimizing the drug-protein interaction, whether it is a small molecule or biologic drug candidate. He also used molecular dynamics simulations to map protein conformational changes in the presence or absence of mutations. Gard did his undergraduate studies at Brigham Young University. He completed his doctorate at the University of Chicago where he studied the interactions and free energies governing proton transport inside cytochrome c oxidase. In his free time, Gard enjoys taking his wife and kids on adventures in the mountains or ocean.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Norman Goodacre

Norman Goodacre

Principal Scientist, Bioinformatics

Norman Goodacre is life-long admirer of nature. This deep connection has guided his professional life, as Norman is a Bioinformatics Scientist with a diverse background in protein-protein interaction prediction, machine learning and single-cell RNA seq analysis. He has worked in academic, government, and start up settings, but prefers the lattermost because of the fast pace of innovation and creative freedom. Modeling the behavior of proteins and their interaction networks keeps Norman up at night.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn
Itai Leven

Itai Leven

Senior Scientist, Computational Chemistry

Itai is a computational chemist specializing in the development of computational tools for large-scale molecular simulations. He earned his PhD in computational chemistry at Tel-Aviv university where he developed intermolecular potentials for conducting large-scale molecular dynamics simulations of nanomaterials. Itai later pursued a post-doc position at the Weizmann institute where he developed a two-state facilitated diffusion model for transcription factor search on DNA. He then joined Teresa Head-Gordon’s lab in UC Berkeley where he developed novel computational tools for predicting the electrostatic properties of molecules with applications to protein-ligand docking and reactive molecular dynamics. In his free time Itai enjoys outdoor activities with his family.

Affiliations

  • Interline Therapeutics

Social Media

  • LinkedIn

Join Our Team

Interline is creating a culture centered around our dual commitments to patients and employees. We prioritize science and innovation, empower one another, and are growing a diverse and inclusive team with individuals united by our common values.